Brokerages Set Health Catalyst, Inc. (NASDAQ:HCAT) Target Price at $11.45

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $11.27.

A number of equities analysts recently weighed in on HCAT shares. Stephens increased their price objective on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 14th. Royal Bank of Canada dropped their price objective on Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a research note on Wednesday. Citigroup lowered their target price on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a report on Friday, January 10th. Evercore ISI boosted their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 price objective on shares of Health Catalyst in a research note on Friday, October 4th.

Insiders Place Their Bets

In other news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.51, for a total transaction of $39,119.59. Following the completion of the sale, the chief operating officer now directly owns 91,253 shares of the company’s stock, valued at approximately $685,310.03. The trade was a 5.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Duncan Gallagher sold 4,500 shares of the stock in a transaction on Monday, December 30th. The shares were sold at an average price of $6.93, for a total value of $31,185.00. Following the completion of the transaction, the director now directly owns 69,938 shares in the company, valued at $484,670.34. This trade represents a 6.05 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 74,727 shares of company stock worth $601,810 in the last 90 days. Corporate insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

Institutional investors have recently added to or reduced their stakes in the business. Quest Partners LLC purchased a new position in Health Catalyst in the third quarter valued at approximately $34,000. Quarry LP boosted its holdings in shares of Health Catalyst by 59.4% in the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after buying an additional 2,610 shares in the last quarter. nVerses Capital LLC purchased a new position in shares of Health Catalyst in the 3rd quarter valued at $59,000. Mackenzie Financial Corp acquired a new stake in Health Catalyst during the 2nd quarter worth $70,000. Finally, Quadrature Capital Ltd purchased a new stake in Health Catalyst in the third quarter valued at $84,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Stock Down 4.5 %

HCAT stock opened at $5.50 on Tuesday. Health Catalyst has a one year low of $5.42 and a one year high of $10.99. The firm has a market cap of $334.68 million, a PE ratio of -4.07 and a beta of 1.36. The firm’s 50 day moving average price is $7.68 and its 200-day moving average price is $7.53. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The business had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. Health Catalyst’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.22) EPS. On average, equities research analysts anticipate that Health Catalyst will post -0.33 EPS for the current year.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.